Metabolic Research, Inc.
OTC Bulletin Board : MTBR

Metabolic Research, Inc.

May 07, 2007 09:01 ET

Metabolic Research, Inc. Announces Agreement for Exclusive Rights to Biomedical Technology

MONTGOMERY, TEXAS--(CCNMatthews - May 7, 2007) - Metabolic Research, Inc. (OTCBB:MTBR) announced today that it has secured an exclusive license to technologies relating to the use of fungi, plants, and/or animals for the production of anti-inflammatory and analgesic products for the treatment of inflammatory diseases from Dr. David Summers and T.W. Owen, the developers of this patented bio-technology process. The irrevocable assignment covers the globe.

Metabolic Research plans to utilize this technology to further its research and development of a new form of natural anti-inflammatory and analgesic products, both pharmaceuticals and nutraceuticals, for the treatment of arthritis and other inflammatory diseases.

In consideration for the assignment, Metabolic Research issued 2.5 million shares of its common stock to Dr. Summers and TW Owen. Thereafter, the Company was restructured and pursuant to a vote of the majority shareholders, Dr. Summers was installed as the new CEO and President and T.W. Owen was installed as CFO, Secretary/Treasurer. Summers and Owen are now the sole members of Metabolic Research's Board of Directors.

"This is a major step for Metabolic Research. This agreement now puts the research and development power of the Metabolic Research team in full control of the biomedical technology TW Owen and I have worked on for years and enabling the company to retain all of the future profits it may gain from the launch of new drugs and treatments developed using this technology. With the total cost for the economy for arthritis estimated to be $128 billion and the estimated overall costs for cancer in at $210 billion, there is clearly a huge market for the types of drugs we hope to be bringing to market," says Dr. David Summers, D.Sc., Ph.D., Chief Executive Officer of Metabolic Research, Inc.

About Metabolic Research, Inc.

Metabolic Research, Inc. intends to develop a new form of pharmaceutical-grade non-synthetic pharmaceuticals to safely and effectively treat inflammatory diseases. Metabolic Research's proprietary process is based on "growing" drugs by using natural metabolic processes of plants or fungus rather than chemical synthesis used by traditional pharmaceutical companies. For more information, please visit the company's website at:

This press release may include "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to have been correct. The Company's actual results could differ materially from those anticipated in the forward-looking statements. The Company refers you to the cautionary statements and risk factors set forth in the documents it files with the Securities and Exchange Commission. Neither the Company or Phoenix IR Associates is under any obligation (and expressly disclaims any obligation) to update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise.

Contact Information